• Deal Headline: GSK completes acquisition of TESARO (22 Jan 2019)
• Deal Type: Acquisition
• Acquirer: GlaxoSmithKline
• Target: TESARO
• Therapeutic Area: Oncology
• Total Deal Size: USD 5100M

GlaxoSmithKline Key BD Contacts

• Senior Vice President, Head of Business Development | Kevin Sin
• Executive Director, Corporate and Business Development | Ian Greenberg
• Vice President and Head of Business Development, North America | Kristen Slaoui

Recent deals:

• Pfizer (Dec 2018)
• Hitachi Chemical Advanced Therapeutics Solutions (Oct 2018)
• Novartis (Jun 2018)
• Kymera Therapeutics (Apr 2018)